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Background: The study describes the methodological challenges encountered in an observational study estimating
the effectiveness of colonoscopy in reducing colorectal cancer (CRC) incidence and mortality.
Methods: Using Ontario provincial administrative data, we conducted a population-based retrospective cohort
study to assess CRC incidence and mortality in a group of average-risk subjects aged 50–74 years who underwent
colonoscopy between 1996–2000. We created two study cohorts; unselected and restricted. The unselected cohort
consists of subjects aged 50–74 years who were eligible for CRC screening and who had the same primary care
physician (PCP) during the period 1996–2000 with at least two years of follow-up. PCPs are general practioners/
family physicians who are the main source of health care for Ontarians. The restricted cohort was a nested sample
of unselected cohort who were alive and free of CRC as on January 1, 2001 and whose PCPs had at least 10 screen-
eligible patients with a colonoscopy referral rate of more than 3%. We compared the outcomes in the two study
cohorts; unselected vs. restricted. We then estimated the absolute risk reduction associated with colonoscopy in
preventing CRC incidence and mortality in the restricted cohort, using traditional regression analysis, propensity
score analysis and instrumental variable analysis.
Results: The unselected cohort (N = 1,341,612) showed that colonoscopy was associated with an increase in CRC
incidence (1.61% vs. 4.61%) and mortality (0.36% vs. 1.16%), whereas the restricted cohort (N = 1,089,998) showed that
colonoscopy was associated with a reduction in CRC incidence (1.36% vs. 0.84%) and mortality (0.23% vs. 0.15%). For CRC
incidence, the absolute risk reduction (ARR) associated with colonoscopy use was 0.52% in an unadjusted model, 0.53%
in a multivariate logistic regression model, 0.54% in a propensity score-weighted outcome model, 0.56% in propensity
score-matched model, and 0.60% using instrumental variable analysis. For CRC mortality, the ARR was 0.08% in the
unadjusted model, multivariate logistic regression model and for a propensity score- weighted outcome model, 0.10%
using propensity score matched model and 0.17% using the IVA model.
Conclusions: Colonoscopy use reduced the risk of CRC incidence and mortality in the restricted cohort. The study
highlights the importance of appropriate selection of study subjects and use of analytic methods for the evaluation of
screening methods using observational data.
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Colorectal cancer (CRC) is the third most common cancer
and has the second highest cancer mortality rate among
Canadian men and women [1,2]. Colonoscopy is consid-
ered an effective tool for CRC screening [3,4] and studies
have shown that colonoscopy is associated with a reduc-
tion of CRC incidence and mortality, but primarily limited
to death due to left sided colon and rectal cancers [5-8].
Due to patient demand [9], reimbursement policies and
economic arguments [10,11] and advocacy by specialty or-
ganizations [12,13], the use of colonoscopy has increased
in the last decade in Canada [14,15]. Despite the increased
use of colonoscopy, its benefit at the population-level is
still uncertain. Evaluating a screening tool and answering
such a policy question using observational data involves
many challenges. Colonoscopy is used in Ontario for a
variety of purposes including screening, diagnosis and sur-
veillance of CRC. It is difficult to distinguish screening
from therapeutic applications of colonoscopy using ad-
ministrative data. Moreover, persons studied using obser-
vational data sources such as electronic administrative
data usually differ in baseline characteristics—both mea-
sured and unmeasured—which are associated with both
treatment assignment as well as their health outcomes.
Hence, using population-based health services information
to estimate the effectiveness of colonoscopy on the risk of
CRC incidence and mortality is prone to various biases.
Failure to account for these biases can lead to incorrect es-
timates of the effectiveness of colonoscopy.
Standard analytic methods such as multivariate logistic
regression can be used to adjust observed differences be-
tween treatment groups for dichotomous outcomes [16].
Propensity score methods are increasingly used for
adjusting selection bias as an alternative to regression ad-
justment and also in health policy studies [17,18]. Both
methods can reduce bias in causal estimates due to ob-
served differences but are still subject to biases from unob-
served differences between treatment groups. Instrumental
variable methods have been used in health policy studies in
the presence of hidden bias [19,20]. While different ana-
lytic methods are available to compare the treatment
groups in observational studies, it is not clear how different
methods yield different findings.
The objective of this paper is to illustrate and compare
different analytic methods and study designs in a study to
estimate the effect of colonoscopy in reducing incidence
and mortality due to CRC using administrative data and
cancer registry information from Ontario, Canada.
Methods
We conducted a population-based retrospective cohort
study to evaluate CRC incidence and mortality associated
with exposure to colonoscopy in a population of Ontario,
Canada who are at risk of CRC. This paper discussesdifferent approaches to patient selection and analytic
methods, to illustrate how different methodologies account
for the biases that complicate efforts to evaluate a screening
test using administrative data in health services research.
Data sources
We used information from several administrative data-
bases and cancer registry. The Registered Persons Data
Base (RPDB) contains the demographic information on all
residents eligible for health care in Ontario. The Ontario
Health Insurance Plan (OHIP) database contains informa-
tion on claims for physicians’ services provided to Ontario
residents, and includes virtually all medical services
provided in Ontario. The Canadian Institute for Health In-
formation–Discharge Abstract Database (CIHI-DAD)
contains information on all discharges from acute care fa-
cilities for residents of Ontario, including patient demo-
graphics, diagnoses, procedures, and discharge status. The
Ontario Cancer Registry (OCR) has records of all Ontario
residents newly diagnosed with cancer or who died from
cancer, and is estimated to be 95% complete [21]. The
2001 Canadian Census files contain aggregated data on
socio-economic information of the Canadian population
at the census tract level. These databases were linked
using an anonymous encrypted number and have very lit-
tle missing information [22].
The study was approved by the Research Ethics Board
of Sunnybrook Health Sciences Centre, Toronto, Canada.
Study subjects
We performed the study using two cohorts of subjects.
First, we created an unselected cohort consisting of all resi-
dents of Ontario aged 50–74 years during the period
1996–2000 and who appeared to be eligible for CRC
screening (no prior diagnosis of CRC, inflammatory bowel
disease (IBD), adenomas, or colonic polyps, no previous
colon or rectal surgery, and no colonoscopy in the previ-
ous 4 years). We included only subjects who had the same
primary care physician (PCP) over the 5 years period with
at least 2 years of follow-up. Subjects who could not be
assigned to an individual PCP using the continuity of care
(COC) method [23,24] (14% of the cohort) were excluded
from this cohort, During the study period, most referrals
to specialists were originated from PCPs. We wanted to
include only patients who could be assigned to a PCP as
our aim was to capture the variation in PCP’s use of colon-
oscopy as an instrument. Subjects residing in areas where
specialist physicians did not submit fee-for-service claims
for colonoscopy (<5% of the cohort) were also excluded.
The details of the areas where physicians do not bill dir-
ectly for services were reported elsewhere [25].
There is a problem measuring screening exposure and
outcomes of patients during the same time period. It is
likely that procedure that have done for diagnostic purposes
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of CRC. In this case, an observational study would counter-
intuitively identify an association between increased colon-
oscopy use and a higher risk of CRC. Therefore we tried
to restrict our cohort and explored the use of a cohort of
subjects whose colonoscopy exposure was measured inde-
pendent of their risk of developing CRC. In the second co-
hort—the restricted cohort—we identified a nested group of
subjects from the unselected cohort who were alive and
free of CRC on January 1, 2001. We excluded patients of
PCPs with fewer than 10 screen-eligible patients and whose
PCPs referred colonoscopy in less than 3% of the patients
linked to them. This exclusion had done to avoid subjects
whose PCPs were not primarily responsible for medical re-
ferrals for their patients. Our intention was not to classify
patients based on their symptoms, or symptomatic versus
asymptomatic subjects. We were interested in studying col-
onoscopy use among patients in whom CRC screening
might be considered. The selection criteria used in the two
cohorts is depicted in Figure 1.Unselected cohort 
Subjects aged 50-74 years and eligible 
for CRC screening  in 1996-2000
N = 2,900,321
Subjects linked to a PCP
N = 2,486,632    (85.7%)
Subjects with same PCP over 5 years
N = 1,834,903     (73.8%)
Subjects with at least 2 years of 
follow-up with the same PCP
N = 1,341,612     (73.1%)
Figure 1 Selection of two cohorts – Unselected cohort vs. Restricted cIdentification of exposure
The occurrence of any colonoscopy procedure during
the period 1996–2000 was the principal exposure. We
identified all colonoscopies performed on the subjects
using OHIP fee codes. Subjects were classified as
the exposed group if there was a receipt of any colon-
oscopy service at any time during the 5 year period
1996–2000.Identification of outcomes
The primary outcomes were cumulative 7-year incidence
and 5-year mortality due to CRC. Cohort subjects were
followed up to December 31, 2007 for CRC incidence and
up to December 31, 2005 for CRC death, to account for
delays in ascertaining cause of death. There was virtually
no loss to follow-up for the outcomes; subjects were cen-
sored at the end of the appropriate follow-up period if
they were still alive. Incident CRC and death due to CRC
was identified in the OCR.Restricted cohort 
Subjects linked to a PCP
N = 2,486,632    (85.7%)
Subjects with same PCP over 5 years
N = 1,834,903     (73.8%)
Subjects with at least 2 years of 
follow-up with the same PCP
N = 1,341,612     (73.1%)
Subjects who are alive and free of 
CRC as of Jan 1, 2001
N = 1,289,543 (96.1%)
Subjects with a PCP who had at least 10 
eligible patients and who screened 3% 
or more of their screen-eligible pts 
N = 1,089,998 (84.6%)
Subjects aged 50-74 years and eligible 
for CRC screening in 1996-2000
N = 2,900,321
ohort.
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Subject characteristics included age, sex, household income
quintile, comorbidity and rural residence, as measured
on 2000. Comorbidity was measured using a modified
Charlson comorbidity Index [26,27] from inpatient claims
diagnosis codes, based on hospital discharges up to four
years prior to their entry into study. Subjects were classi-
fied as having no inpatient claims, or being hospitalized
with no comorbidities and being hospitalized with one or
more comorbidities. Census 2001 data were used to obtain
neighborhood household income quintile. Neighborhood
income is calculated by Statistics Canada and is available
by dissemination area (DA), which is the smallest geo-
graphic area for which census data are made available.
Each patient’s DA of residence was identified based on
their postal code and then linked to the Statistics Canada
postal code conversion file to get the neighborhood income
[25]. This variable was used as an ecological measure of
socioeconomic status of subjects.Statistical analysis
We first performed a descriptive analysis of the two study
cohorts. We estimated the absolute risk reduction (ARR)
and 95% confidence intervals for development of CRC out-
comes between those subjects who received a colonoscopy
and those who did not.
Since CRC outcomes are influenced not only by use of
colonoscopy, but also by many other measured determi-
nants of colonoscopy, we then used logistic regression ana-
lysis with generalized estimating equation (GEE) models to
adjust for measured confounding factors and the clustering
of subjects within PCPs. In addition to colonoscopy expos-
ure, models included the subject level covariates age, sex,
Charlson comorbidity score, rural area of residence and in-
come quintile to adjust for differences in baseline risk. The
c-statistic was used to measure predictive validity of differ-
ent models.
Third, we performed propensity score (PS) analyses in
the Restricted Cohort. Since selection bias influences
whether a person has a colonoscopy, comparing outcome
events between subjects who had a colonoscopy and those
who did not by means of conventional statistical modeling
such as multivariate logistic analysis will still yield biased
estimates of effect [16]. To adjust for the potentially
confounding factors and selection bias due to non-random
allocation of subjects to two groups, propensity scores
[28,29] were calculated. The conditional probability that
each person would have received a colonoscopy was esti-
mated using multivariable logistic regression model, using
the following as predictor variables: age, sex, neighborhood
income quintile, co-morbidity index and rural residence.
The c-statistic for the propensity score derivation model
was 0.80, indicating good model discrimination. This modelestimated the adjusted predicted probabilities (propensity
scores) of colonoscopy use for each subject.
We explored three methods of propensity score analysis:
(1) Quintile stratification analysis (Crude analysis of CRC
outcomes based on PS quintile approach [18,30], stratifying
subjects into 5 equal categories based on the propensity
scores); (2) Propensity score weighted analysis (Using the
“inverse probability of treatment weight [IPTW]” method
[31,32], the PS was weighted by the inverse of the PS for
subjects who had a colonoscopy and by the inverse of 1-PS
for subjects without a colonoscopy. The probability of
CRC incidence and mortality associated with colonoscopy
use was estimated using a propensity score-weighted logis-
tic regression model, controlling for other covariates.); and
(3) Propensity score matched analysis (We used a greedy
matching algorithm [33,34] to individually match persons
receiving colonoscopy to unique persons who did not
according to their propensity scores [35], yielding 86,592
matched pairs. Differences in the explanatory variables
between those received and did not receive colonoscopy
were tested using chi-square statistic. Standardized dif-
ferences of the 2 groups were used to describe the treat-
ment effect, with standardized differences greater than
10% considered meaningful [36]. CRC incidence and
mortality differences between the two groups were esti-
mated overall and for demographically defined sub-
groups using Kaplan-Meier survival curves. They were
tested for their homogeneity with the Wilcoxon signed
rank test for matched pairs. Differences in 7-year inci-
dence and 5-year mortality rates were assessed using
the McNemar test.)
Finally, we performed a fourth set of analyses using in-
strumental variables. Originally described in econometrics
[19], instrumental variable analysis (IVA) is increasingly
used in epidemiologic and health-service research studies
[37-39] to balance the treatment groups to address hidden
treatment selection bias. In theory, IVA addresses both the
measured and unmeasured differences between the two
groups. While the three previous analytic approaches con-
sidered measured confounders that might have influenced
colonoscopy use, they could not account for any unmeas-
ured factors. IVA estimates treatment effects in the pres-
ence of unmeasured hidden confounding [40,41], and is
suited to health policy questions [42,43].
An instrumental variable should be strongly associated
with the exposure, but not an independent determinant of
the outcome of interest [44]. We used the PCP rate of dis-
cretionary colonoscopy as the instrumental variable for
our analyses. “Discretionary colonoscopy” was defined as a
colonoscopy procedure on a person without known risk
factors for colorectal cancer, not performed during an in-
patient stay, and not associated with a diagnosis of colo-
rectal cancer at the time of colonoscopy or within a 3 year
period following the colonoscopy. We assigned each PCP
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of discretionary colonoscopies per 100 eligible persons
linked to him or her during 1996–2000. The PCP rate of
discretionary colonoscopy has very useful properties as an
instrument. It is highly correlated with receipt of colonos-
copy and by definition is uncorrelated with CRC incidence
and mortality, except for its association with colonoscopy.
In the first stage of IV method, we predicted exposure to
colonoscopy using the instrument and the subject level
covariates. The predicted probability of receiving colonos-
copy was then used as an independent variable in the sec-
ond stage to predict CRC incidence and mortality, along
with other subject level measured covariates. To account
for the clustering of subject-level observations, parameters
and standard errors were estimated robustly using a gen-
eralized estimating equation approach. The strength of the
instrumental variable was examined using the OR and
log-likelihood tests from first stage model, yielding a par-
tial F-statistic of 10.
We reported the predicted probabilities in percentages
with 95% confidence intervals for each statistical method
used and absolute risk reduction ARR with 95% confidence
intervals. P values less than 0.05 were considered statisti-
cally significant. All analyses were performed using SAS
version 9.2.
Results
Comparison of outcomes in different cohorts
There were 1,341,612 subjects in the unselected cohort be-
tween the age of 50–74 years and 97,740 (7.3%) were ex-
posed to a colonoscopy. There were 24,559 new cases and
5,556 deaths due to CRC from this cohort during theTable 1 Probability of CRC incidence and mortality in the two
Study cohorts Colonoscopy














Data are presented as percentages.
CRC, colorectal cancer; CI, confidence interval.follow up period. Of the 1,089,998 subjects in the restricted
cohort, 86,837 (8.0%) had a colonoscopy during the period
1996–2000. By definition, none of these colonoscopies
resulted in a diagnosis of CRC. There were 14,455 (1.3%)
new diagnosis of CRC and 2,394 (0.3%) deaths of CRC in
the restricted cohort during the period.
Table 1 shows the observed probability for CRC inci-
dence and mortality according to the receipt of colonos-
copy in the two study cohorts. In the unselected cohort,
the proportion of new cases of CRC in the colonoscopy
group was 4.61% as compared with 1.61% in the no colon-
oscopy group, suggesting that colonoscopy increases the
risk of CRC. Similarly, the proportion of death shows an
increased likelihood of mortality among the colonoscopy
users compared to non-users (1.16% vs. 0.36%). Clearly,
there is no plausible explanation for why colonoscopy
should be a risk factor for CRC. However, persons newly
diagnosed with CRC will very commonly be exposed to
colonoscopy, for the purpose of diagnosis, confirmation, or
pre-operative planning. In this unselected cohort, subjects
with colonoscopies that are performed for the diagnosis
and symptoms of CRC were included, which could have
resulted in this bias.
We then explored the possibility of this bias by ana-
lyzing the restricted cohort. The restricted cohort shows
a reduction in incidence (0.84% vs. 1.36%) and mortality
(0.15% vs. 0.23%) among the colonoscopy users com-
pared to nonusers. There was an ARR of 0.52% for inci-
dence and 0.08% for mortality in favor of colonoscopy.
These results demonstrate how different methodologies
in creating study cohorts change the causal relationship
of treatment effect.cohorts - Unadjusted model
Estimate 95% CI Absolute risk difference 95% CI
1.61 1.59, 1.63 3.00 2.69, 3.30
4.61 4.31,4.91
0.36 0.33, 0.38 0.80 0.73, 0.87
1.16 1.10, 1.23
1.36 1.35, 1.39 -0.52 -0.60, -0.46
0.84 0.77, 0.91
0.23 0.19, 0.27 -0.08 -0.13, -0.03
0.15 0.12, 0.17
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Table 2 shows the predicted probabilities of CRC inci-
dence and mortality for the two study cohorts using multi-
variate logistic regression with a GEE approach, adjusted
for patient age, sex, neighborhood income quintile, co-
morbidity and rural residence. The predicted probabilities
were calculated for each subject and then averaged for the
population. The unselected cohort had an increased CRC
incidence and mortality in the colonoscopy group even
after adjusting for measured subject-level confounding
factors, whereas the restricted cohort shows a reduction in
CRC outcomes in the colonoscopy group. The remaining
analyses were done only for the restricted cohort.
Propensity score analyses
Quintile stratification analysis
Figure 2 shows the incidence and mortality rates by pro-
pensity score quintiles for colonoscopy use. In all the quin-
tiles, the incidence rate and mortality rates were lower in
patients who received colonoscopy than in those did not.
Propensity score matched analysis
Table 3 compares the baseline characteristics of subjects
with and without colonoscopy in the restricted cohort and
the PS matched cohort. In the restricted cohort, the colon-
oscopy users were more likely to be women, live in rural
areas and areas with high neighborhood household in-
come. The proportion of patients with comorbidity was
higher in the colonoscopy group. The PS matched cohort
with 86,592 colonoscopy users and nonusers, were similar
with respect to all the measured characteristics.Table 2 Predicted probabilities of CRC incidence and mortalit
model
Study cohorts Colonoscopy














Data are presented as percentages.
CRC, colorectal cancer; CI, confidence interval.
Multivariate logistic model adjusted subject characteristics such as age, sex, charlsoFigure 3 shows the cumulative CRC incidence and
mortality for the PS matched cohort. The colonoscopy
users were less likely to have developed or died of CRC
at each time point. For example, cumulative incidence
rates were 0.14% in colonoscopy users versus 0.17% in
nonusers at 1 year and 0.87% versus 1.43% at 5 years.
The mortality relative reduction was 15% at 1 year and
39% at 5 years (P < 0.001).
Table 4 shows the cumulative CRC incidence and mortal-
ity among colonoscopy users and matched nonusers for the
PS matched cohort according to age and sex. All groups
had lower incidence and mortality among colonoscopy
users than among matched nonusers. The incidence and
mortality reductions increased with age and were greater in
men than women in each age group. The cumulative re-
duction in 7-year incidence and 5-year mortality was
greater in men than women. There was a greater reduction
in incidence and mortality in lower income quintiles.
Propensity score weighted analysis
The predicted probabilities for both incidence (Table 5) and
mortality (Table 6) using PS weighted outcome analysis
were higher than the unadjusted model suggesting the ef-
fect of confounders in the model.. However, the absolute
risk differences were similar to the unadjusted model.
Instrumental variable analyses
Using IVA, the predicted probability for CRC incidence
in the colonoscopy and no colonoscopy groups were
0.65% and 1.25% respectively, which were lower than the
unadjusted estimates (Table 5). Similarly the predictedy in the two cohorts - Multivariate logistic regression
Estimate 95% CI Absolute risk difference 95% CI
1.75 1.73, 1.77 3.26 3.22, 3.30
5.01 4.97, 5.04
0.38 0.33, 0.42 0.79 0.71, 0.87
1.17 1.10, 1.23
1.42 1.39, 1.44 -0.53 -0.60, -0.44
0.90 0.82, 0.98
0.24 0.18, 0.29 -0.08 -0.19, 0.04
0.16 0.13, 0.34






































































Figure 2 Comparison of incidence and mortality rate by subject colonoscopy status and propensity score quintiles – Restricted cohort.
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(Table 6). The corresponding ARR was 0.60% (95% CI: -
0.78, -0.31) for incidence and 0.17% (95% CI: -0.21, -0.14)
for mortality, higher than the unadjusted model.Comparison of methods
Table 5 also compares the reduction in CRC incidence as-
sociated with colonoscopy for the restricted cohort using
different statistical methods. The predicted probabilities
for CRC incidence in the logistic model, PS weighted out-
come model and PS matched models were higher than the
unadjusted model, whereas the IVA estimates were lower
than the unadjusted model. (Table 5) The absolute risk re-
duction in an unadjusted analysis was 0.52% (95% CI;
0.60%, 0.46%) for CRC incidence. With adjustment for
age, sex, income quintile, rural area of residence and co-
morbidity using logistic regression the ARR increasedslightly to 0.53%, but did not change meaningfully. Next,
the propensity score weighted outcome model and PS
matched analysis produced slightly higher risk reductions
with ARR of 0.54% and 0.56% respectively. The final
model using IVA method produced an ARR of 0.60%
suggesting the effect of hidden confounding in the model.
Table 6 compares the reduction in CRC mortality associ-
ated with colonoscopy for the restricted cohort using differ-
ent statistical methods. The predicted probabilities for CRC
mortality were higher in all models except IVA compared
to the unadjusted model. The ARR for CRC mortality was
0.08% for unadjusted model, multivariate model and for PS
weighted outcome model. It increased up to 0.17% using
the IVA model with a 95% CI of -0.21, -0.14. The reduc-
tions for both incidence and mortality were larger in IVA
than other analyses. This was expected as the predicted
probability of exposure changed from a dichotomous level
to a range of values from 0 to 1. Also, IVA yields an ARR
Table 3 Comparison of baseline characteristics according to receipt of colonoscopy – Restricted cohort vs. PS Matched
cohort

















# of patients 1,089,998 1,003,161 86,837 86,592 86,592




50-59 461,161 (42.3) 425,29 1 (42.4) 35,870 (41.3) 2.23% 35,695 (41.2) 35,775 (41.3) 0.20%
60-69 379,961 (34.9) 344,492 (34.3) 35,469 (40.9) 13.66% 35,289 (40.8) 35,365 (40.8) 0.00%
70-74 248,876 (22.8) 233,378 (23.3) 15,498 (17.9) 13.38% 15,608 (18.0) 15,452 (17.8) 0.52%
Income quintile <.001 0.75
01 187,006 (17.2) 173,598 (17.3) 13,408 (15.1) 5.97% 13,230 (15.3) 13,407 (15.5) 0.55%
02 219,705 (20.1) 203,403 (20.3) 16,302 (18.7) 4.04% 16,378 (18.9) 16,300 (18.8) 0.26%
03 220,765 (20.3) 203,512 (20.3) 17,253 (19.9) 1.00% 17,326 (20.0) 17,251 (19.9) 0.25%
04 219,289 (20.1) 201,626 (20.1) 17,663 (20.5) 0.99% 17,587 (20.3) 17,663 (20.4) 0.25%
05 240,663 (22.1) 218,691 (21.8) 21,972 (25.7) 9.17% 22,071 (25.5) 21,971 (25.4) 0.23%
Missing 2,570 (0.3) 2,331 (0.2) 239 (0.3)
Rural area
of residence





519,817 (47.7) 514,294 (51.3) 5,523 (6.4) 114.09% 5,516 (6.4) 5,516 (6.4) 0.00%
401,168 (36.8) 337,586 (33.6) 63,582 (73.2) 86.49% 63,752 (73.6) 63,415 (73.2) 0.91%
At least one
comorbidity
169,013 (15.5) 151,281 (15.1) 17,732 (20.4) 13.90% 17,324 (20.0) 17,661 (20.4) 1.00%
Data are presented as number (percentage). Standardized difference is the mean difference divided by the pooled SD, expressed as a percentage.
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to be different than the average population.
Discussion
We studied methodological approaches to addressing se-
lection and measurement bias in a population-based
study of the effectiveness of colonoscopy use in the pre-
vention of CRC incidence and mortality. First, we com-
pared the outcomes in an unselected cohort of subjects
in whom exposure to colonoscopy was measured during
the same time period that outcomes were ascertained,
and also among subjects in a restricted cohort when ex-
posure was not measured during the same period of
time that outcome events were measured. The unse-
lected cohort showed a paradoxical increase in CRC in-
cidence (4.61% vs. 1.61%) and mortality (1.16% vs.
0.36%) associated with colonoscopy use, whereas the re-
stricted cohort showed a reduction in incidence (0.84%
vs. 1.37%) and mortality (0.15% vs. 0.23%) among colon-
oscopy users compared to nonusers.
We then explored different methods of analysis of the
restricted cohort, using a conventional regression model,propensity score analysis, and instrumental variable ana-
lysis, to adjust for potential confounding factors and se-
lection bias due to non-random allocation of study
subjects. For CRC incidence, the absolute risk reduction
associated with colonoscopy use was 0.52% in an un-
adjusted model, 0.53% in a multivariate logistic model,
0.54% in a propensity score-weighted outcome model,
0.56% in propensity score-matched model, and 0.60%
using instrumental variable analysis. For CRC mortality,
the ARR was 0.08% in the unadjusted model, multivari-
ate model and for a propensity score- weighted outcome
model, 0.10% in propensity score-matched model and
0.17% using the IVA model. Using all the above models,
we found that colonoscopy was beneficial in reducing
the risk of CRC incidence and mortality in the restricted
cohort even after adjustment for important biases such
as treatment selection and hidden biases.
The different results between the two study cohorts
are likely due to measurement error. When we looked at
the subjects in unselected cohort that were not in the re-
stricted cohort, we found that these were subjects with a



















































Figure 3 Estimates of cumulative Incidence and Mortality Rates for Propensity Matched Cohort. Note: Differences in cumulative rates
between colonoscopy user and nonusers at each time point shown after 12 months were significant (p < 0.001).
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the challenge of not being able to differentiate screening
from diagnostic tests. In the unselected group, colonos-
copies performed for the diagnosis of symptoms and
signs of colorectal cancer could not be excluded and in-
clusion of these patients resulted in bias. The increasedTable 4 Cumulative CRC incidence and mortality rates for PS
Cumulative incidence rates
Participant groups Colonoscopy users Nonusers D
All matched pairs 0.87% 1.43%
By Sex and age group
Men 0.99% 1.81%
Age 50-S9y 0.55% 1.10%
Age 60-69y 1.16% 1.93%
Age 70-74y 1.72% 3.41%
Women 0.78% 1.13%
Age 50-59y 0.40% 0.54%
Age 60-69y 0.97% 1.36%







CRC, colorectal cancer; PS, propensity score.risk of CRC among patients who had colonoscopy in the
unselected cohort is mostly attributable to inclusion of
colonoscopies performed in persons with symptoms of
CRC.
In subsequent analyses using only the restricted co-
hort, we found reductions in 7-year incidence and 5-yearmatched cohort
Cumulative mortality rates
ifference Colonoscopy users Nonusers Difference
0.56% 0.15% 0.23% 0.08%
0.82% 0.16% 0.29% 0.13%
0.56% 0.11% 0.14% 0.03%
0.77% 0.17% 0.32% 0.15%
1.69% 0.27% 0.62% 0.35%
0.35% 0.14% 0.18% 0.05%
0.14% 0.05% 0.04% 0.01%
0.39% 0.19% 0.22% 0.03%
0.81% 0.22% 0.46% 0.24%
0.68% 0.14% 0.32% 0.18%
0.72% 0.17% 0.28% 0.11%
0.44% 0.18% 0.22% 0.05%
0.51% 0.12% 0.20% 0.07%
0.50% 0.13% 0.18% 0.06%
Table 5 Risk reductions in CRC incidence § associated with colonoscopy - comparison of different methods
Model Predicted probability (95% Cl) Absolute risk reduction (95% Cl)
No colonoscopy Any colonoscopy
Unadjusted Model 1.36 (1.35, 139) 0.84 (0.77, 0.91) −0.52 (−0.60, −0.46)
Multivariate Logistic Regression Model† 1.42 (1.39, 1.44) 0.90 (0.82, 0.98) −0.53 (−0.60, −0.44)
Propensity Score Weighted Model‡ 1.40 (1.37, 1.42) 0.86 (0.83, 0.89) −0.54 (−0.69, −0.39)
Propensity Score Matched Model∞ 1.43 (1.33, 1.52) 0.87 (0.76, 0.98) −0.56 (−0.99, −0.12)
IV Adjusted Model∂ 1.25 (1.19, 1.30) 0.65 (0.41, 0.99) −0.60 (−0.78, −0.31)
Data are presented as percentages.
CRC, colorectal cancer; CI, confidence interval.
† Multivariate logistic model adjusted subject characteristics such as age, sex, charlson comorbidity index, rural area of residence and income quintile.
‡ Propensity score weight calculated as 1/ps for colonoscopy users and 1/(1-ps) for the non users.
∞ PS matched model on 86,592 pairs.
∂ IV adjusted probabilities were estimated using 2-stage probit models. In the first stage, the probability of receiving colonoscopy was modeled as a function of
the PCP rate of colonoscopy. In the second stage, the probability of CRC incidence and mortality was modeled using the predicted probability of colonoscopy as
an independent variable, adjusted for PCP and subject characteristics.
§ Incidence up to 7 years.
**Negative values indicate a reduction in the absolute risk of CRC incidence.
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even though the ARR did not vary much for all methods
other than the IVA.
The standard multivariate logistic regression method as-
sumes that the relationship between the risk factors and
outcome are correctly specified in the model and all rele-
vant baseline risk factors have been measured. However, in
many situations these assumptions are not met because it
is impossible to measure all important risk factors. It is also
difficult to know whether the relationships between risk fac-
tors and outcome are correctly specified in the model. The
results from this standard analysis can be used to compare
the results from other method for model misspecification
and unmeasured confounding.
Propensity score quintile analysis, which is another way
to address potential model misspecification and selection
bias, is less parametric compared to standard regression.
This method compares the outcomes across different
groups of patients with similar propensity to receive the
colonoscopy. Stratification based on quintiles of propensityTable 6 Risk reductions in CRC mortality § associated with co
Model Predicted prob
No colonoscopy
Unadjusted Model 0.23 (0.19, 0.27)
Multivariate Logistic Regression Model† 0.24 (0.18, 0.29)
Propensity Score Weighted Model‡ 0.25 (0.20, 0.29)
Propensity Score Matched Model∞ 0.27 (0.05, 0.49)
IV Adjusted Model∂ 0.21 (0.17, 0.26)
Data are presented as percentages.
CRC, colorectal cancer; CI, confidence interval.
† Multivariate logistic model adjusted subject characteristics such as age, sex, charls
‡ Propensity score weight calculated as 1/ps for colonoscopy users and 1/(1-ps) for
∞ PS matched model on 86,592 pairs.
∂ IV adjusted probabilities were estimated using 2-stage probit models. In the first
the PCP rate of colonoscopy. In the second stage, the probability of CRC incidence
an independent variable, adjusted for subject characteristics.
§ Mortality up to 5 years.
**Negative values indicate a reduction in the absolute risk of CRC mortality.scores removes more than 90% of the bias [29]. This
method attempts to balance the observed characteristics in
the exposed groups as would occur in a randomized experi-
ment [45]. The method is drawn from the same discipline
of standard regression which assumes that all relevant base-
line risk factors have been measured and correctly specified
in the model. However, in many situations these assump-
tions are not met and there can be unmeasured con-
founders that can affect the exposure of interest.
The Propensity score weighted analysis produced similar
estimates of the standard method suggesting that the
standard model has adjusted correctly for any differences
in measured covariates. The Propensity score weighted
analysis uses the inverse of the propensity score to weight
each observation in the exposed group, and one minus the
inverse of the propensity score (i.e., the propensity of NOT
being in the treated group) in the non exposed group.
Weighting has the advantage of including all the data (un-
less weights are set to 0) and does not depend on sampling
or matching. While this method has useful mathematicallonoscopy -comparison of different methods
ability (95% Cl) Absolute risk reduction (95% Cl)
Any colonoscopy
0.15 (0.12, 0.17) −0.08 (−0.13, −0.03)
0.16 (0.13, 0.34) −0.08 (−0.19, −0.04)
0.17 (0.11, 0.23) −0.08 (−0.15, −0.02)
0.17 (0.01, 0.41) −0.10 (−1.24, −1.04)
0.04 (0.01, 0.12) −0.17 (-0.21, −0.14)
on comorbidity index, rural area of residence and income quintile.
the non users.
stage, the probability of receiving colonoscopy was modeled as a function of
and mortality was modeled using the predicted probability of colonoscopy as
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subject happens to have a very low probability of being
treated, the value of the inverse of the propensity score will
be extremely high, asymptotically infinity [31]. The effect
size obtained will be dominated by this single value, and
any fluctuations in it will produce wildly varied results,
which is an undesirable property.
The PS matching method produced an absolute reduc-
tion of 0.56% for CRC incidence and 0.10% for CRC mor-
tality, which are larger than the standard method.
However, the confidence intervals are very wide and over-
lap the confidence regions. The reduced sample size due to
matching could lead to less précised results. Matching is a
method for sampling a large reservoir of potential controls
to produce a control group of modest size that is ostensibly
similar to the treated group. In practice, there is a trade-off
between the desires to find matches for all treated units
and to obtain matched treated-control pairs that are ex-
tremely similar to each other. While the PS matching
method addresses the overt bias, it does not address or re-
solve confounding due to unmeasured factors. It also
leaves a small residual bias due to inexact matching.
Our IVA findings highlighted the important role of PCP
in cancer screening. The inadequacy of adjustment for only
measured confounders is evidenced by the fact that the
IVA estimate of the absolute difference of 0.60% for CRC
incidence was larger than other methods. Similarly, the
ARR for CRC mortality was 0.08% for the standard model,
and it increased up to 0.17% using the IVA model. The
confidence intervals are wider than the standard model
which is expected as the IV approach depends on much
less variation in user status [16]. We suspect that there is
bias coming from the unmeasured variables that are asso-
ciated with physicians’ use of colonoscopy. In our previous
study we showed there are significant variations with re-
spect to PCP use of colonoscopy [14]. Another reason for
the difference in estimates is that IVA calculates only the
marginal effect on the population under study, which dif-
fers from the average effect. The marginal population [43]
excludes persons who would “always” or “never” receive
colonoscopy, focusing on patients whose indication for col-
onoscopy is more discretionary. Hence the reduction is for
the intermediate risk group for whom colonoscopy is not
required for complications or symptoms due to CRC yet
the benefit of colonoscopy is uncertain. Thus, IVA is well
suited for policy questions, rather than addressing the ef-
fect on a particular patient. Its external validity depends on
the population studied. The variable we used-PCP rate of
discretionary colonoscopy- meets the assumptions of a
valid instrument as PCP’s practice of screening colonos-
copy is highly correlated with the individual level receipt of
colonoscopy among their subjects. In addition, because of
the way we defined discretionary colonoscopy—by defin-
ition, a discretionary colonoscopy cannot occur in a patientwho subsequently develops CRC—a PCP’s rate of discre-
tionary colonoscopy is not independently associated with
the risk of CRC among his or her patients.
The challenge in IVA is to identify a good valid instru-
ment. It is often conceptually credible to assume the lack
of association between the instrument and outcome, but
impossible to verify empirically or statistically. We ex-
plored other instruments for use in the study, such as geo-
graphical region of residence, time period, and intensity of
health services use. The PCP rate of discretionary colonos-
copy was the variable with the best theoretical attributes
of an instrumental variable, and was associated with the
most variation in the receipt of colonoscopy.
Our study has several limitations. First, we have not in-
cluded the 25% of the Ontario population without a usual
provider of care. These subjects may have a very low rate
of colonoscopy as well as CRC screening, as they do not
have an opportunity to receive such recommendations
from their PCP [46]. Second, because of the cross-
classified structure of the data, patients may not be com-
pletely nested within physicians. To address this limitation,
we included only patients who had the same PCP over the
5 year period from 1996–2000. Third, our definition of
COC required patients to have at least 2 visits with a PCP
per year to be linked to a PCP. We did not include the
small number of apparently healthy patients who had only
1 or no visits per year. Fourth, some potential confounders
were not directly measured in our study, such as a family
history of CRC. Fifth, we did not consider other types of
screening in our study, such as fecal occult blood test or
flexible sigmoidoscopy. Because we focused only in the po-
tential benefits of colonoscopy and not the potential
harms, any estimates of the overall benefit of colonoscopy
should explicitly incorporate both benefits and risks. Fi-
nally, we did not account for variation in technique of col-
onoscopy. The impact of colonoscopy in the diagnosis of
CRC depends on the quality of the examination. In our
study, 83% of all colonoscopies were classified as complete.
Overall, however, the limitations of our study design do
not substantially affect our ability to accomplish our princi-
pal research objective of estimating the population level ef-
fect of colonoscopy. Our results are estimates of the effect
of colonoscopy use in typical practice settings. Our findings
could help other researchers in the design and analysis of
studies which test other screening methods.
Conclusion
In conclusion different methods of subject selection
and statistical analysis provided different estimates of
the effectiveness of colonoscopy. It is very important to
understand the sources of bias and how design and ana-
lytic strategies can impact study findings, particularly
with the use of administrative data for evaluating
screening modalities.
Jacob et al. BMC Medical Research Methodology 2013, 13:59 Page 12 of 13
http://www.biomedcentral.com/1471-2288/13/59Competing interests
The authors declare that they have no competing interests.Authors’ contributions
BJJ was responsible for the data collection, analyses and interpretation of data,
drafting the manuscript and the process of seeking funding. NNB made
significant contributions to interpretations of data and also took part in editing
the manuscript. RM and RS were the resource persons for statistical analysis,
assisted with interpretation of the data and helped in editing the manuscript.
DRU was responsible for the conception and design of study, and manuscript
finalizing. All of the authors read and approved the final manuscript.Acknowledgements
This study was funded by grants from the Canadian Institutes of Health
Research (CIHR) and Colon Cancer Canada (CCC). This study was supported
by the Institute for Clinical Evaluative Sciences (ICES), which is funded by an
annual grant from the Ontario Ministry of Health and Long-Term Care
(MOHLTC). The opinions, results and conclusions reported in this paper are
those of the authors and are independent from the funding sources. No
endorsement by ICES or the Ontario MOHLTC is intended or should be
inferred. Nancy Baxter holds the Cancer Care Ontario Health Services
Research Chair and an Early Researchers Award from the Ontario Ministry of
Research and Innovation.
Author details
1Division of Support, Systems and Outcomes, Toronto General Hospital, 200
Elizabeth Street, Toronto, ON M5G 2C4, Canada. 2Institute of Medical Science,
University of Toronto, Toronto, Canada. 3Institute for Clinical Evaluative
Sciences, Toronto, Canada. 4Dalla Lana School of Public Health, University of
Toronto, Toronto, Canada. 5Department of Family and Community Medicine,
University of Toronto, Toronto, Canada. 6Department of Surgery and Keenan
Research Centre, Li Ka Shing Knowledge Institute, St. Michael’s Hospital,
Toronto, Canada. 7Department of Health Policy Management Evaluation,
University of Toronto, Toronto, Canada. 8Cancer Care Ontario, Toronto, ON,
Canada. 9Department of Surgery, University of Toronto, Toronto, Canada.
Received: 9 March 2012 Accepted: 5 April 2013
Published: 24 April 2013References
1. Canadian Cancer Society/National cancer Institute of Canada: Canadian
Cancer Statistics 2010. Toronto, Canada: CCS/NCIC; 2010. http://www.cancer.
ca/en/cancer-information/cancer-101/canadian-cancer-statistics-publication/.
2. Public Health Canada Statistics; 2010. http://www.phac-aspc.gc.ca/publicat/
ncccs-cndcc/ccsrec-eng.php.
3. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G: Use of
colonoscopy to screen asymptomatic adults for colorectal cancer.
Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000,
343:162–168.
4. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, et al: Colorectal
cancer screening and surveillance: clinical guidelines and rationale-
Update based on new evidence. Gastroenterology 2003, 124:544–560.
5. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L:
Association of colonoscopy and death from colorectal cancer. Ann Intern
Med 2009, 150:1–8.
6. Brenner H, Hoffmeister M, Arndt V, Stegmaier C, Altenhofen L, Haug U:
Protection from right- and left-sided colorectal neoplasms after
colonoscopy: population-based study. J Natl Canc Inst 2010, 102:89–95.
7. Singh H, Nugent Z, Demers AA, Kliewer EV, Mahmud SM, Bernstein CN: The
reduction in colorectal cancer mortality after colonoscopy varies by site
of the cancer. Gastroenterology 2010, 139:1128–1137.
8. Jacob B, Moineddin R, Sutradhar R, Baxter N, Urbach D: Effect of
colonoscopy on colorectal cancer incidence and mortality: an instrumental
variable analysis. Gastrointest Endosc 2012, 76(2):355–364. Under review.
9. Meissner HI, Breen N, Klabunde CN, Vernon SW: Patterns of colorectal
cancer screening uptake among men and women in the United States.
Canc Epidemiol Biomark Prev 2006, 15:389–394.
10. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM: Cost-effectiveness of screening
for colorectal cancer in the general population. JAMA 2000, 284:1954–1961.11. Hassan C, Di GE, Pickhardt PJ, Zullo A, Laghi A, Kim DH, et al: Cost
effectiveness of colonoscopy, based on the appropriateness of an
indication. Clin Gastroenterol Hepatol 2008, 6:1231–1236.
12. Winawer SJ, Zauber AG, Fletcher RH, Stillman JS, O'brien MJ, Levin B, et al:
Guidelines for colonoscopy surveillance after polypectomy: a consensus
update by the US Multi-Society Task Force on Colorectal Cancer and the
American Cancer Society. Gastroenterology 2006, 130:1872–1885.
13. Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, et al:
Screening and surveillance for the early detection of colorectal cancer
and adenomatous polyps, 2008: a joint guideline from the American
Cancer Society, the US Multi-Society Task Force on Colorectal Cancer,
and the American College of Radiology. Gastroenterology 2008,
134:1570–1595.
14. Jacob BJ, Baxter NN, Moineddin R, Sutradhar R, Del GL, Urbach DR: Social
disparities in the use of colonoscopy by primary care physicians in
Ontario. BMC Gastroenterol 2011, 11:102.
15. Vinden C, Schultz S, Rabeneck L: Use of bowel procedures in Ontario: ICES
Atlas. Toronto: Institute for Clinical Evaluative Sciences; 2004.
16. Posner MA, Ash AS, Freund KM, Moskowitz MA, Shwartz M: Comparing
Standard Regression, Propensity Score Matching, and Instrumental
Variables Methods for Determining the Influence of Mammography on
Stage of Diagnosis. Health Serv Outcome Res Meth 2001, 2:279–290.
17. Connors AF Jr, Speroff T, Dawson NV, Thomas C, Harrell FE Jr, Wagner D,
et al: The effectiveness of right heart catheterization in the initial care of
critically ill patients. SUPPORT Investigators. JAMA 1996, 276:889–897.
18. D'Agostino RB Jr: Propensity score methods for bias reduction in the
comparison of a treatment to a non-randomized control group. Stat Med
1998, 17:2265–2281.
19. Newhouse JP, McClellan M: Econometrics in outcomes research: the use
of instrumental variables. Annu Rev Publ Health 1998, 19:17–34.
20. McIntosh MW: Instrumental variables when evaluating screening trials:
estimating the benefit of detecting cancer by screening. Stat Med 1999,
18:2775–2794.
21. Robles SC, Marrett LD, Clarke EA, Risch HA: An application of capture
recapture methods to the estimation of completeness of cancer
registration. J Clin Epidemiol 1988, 41:495–501.
22. Institute for Clinical Evaluative Sciences: Improving health care data in
Ontario: ICES investigative report. Toronto: ICES; 2005.
23. Bice TW, Boxerman SB: A quantitative measure of continuity of care. Med
Care 1977, 15:347–349.
24. Shortell SM: Continuity of medical care: conceptualization and
measurement. Med Care 1976, 14:377–391.
25. Primary Care in Ontario: Institute for Clinical Evaluative Sciences (ICES) Atlas.
Toronto: ICES; 2006.
26. Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for
use with ICD-9-CM administrative databases. J Clin Epidemiol 1992,
45:613–619. -619.
27. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of
classifying prognostic comorbidity in longitudinal studies: development
and validation. J Chronic Dis 1987, 40:373–383.
28. Rubin DB: Estimating causal effects from large data sets using propensity
scores. Ann Intern Med 1997, 127:757–763.
29. Rosenbaum P, Rubin D: The central role of the propensity score in
observational studies for causal effects. Biometrika 1983, 70:41–55.
30. Grzybowski M, Clements EA, Parsons L, Welch R, Tintinalli AT, Ross MA, et
al: Mortality benefit of immediate revascularization of acute ST-
segment elevation myocardial infarction in patients with
contraindications to thrombolytic therapy: a propensity analysis1. JAMA
2003, 290:1891–1898.
31. Hogan JW, Lancaster T: Instrumental variables and inverse probability
weighting for causal inference from longitudinal observational studies.
Stat Meth Med Res 2004, 13:17–48.
32. Leslie R, Ghomrawi H: The Use of Propensity Scores and Instrumental Variable
Methods to Adjust For Treatment Selection Bias. SAS Global Forum: Statistics
and Data Analysis; 2008.
33. Kosanke J, Bergstralh E: Match one or more controls to cases using the
GREEDY algorithm. Rochester, MN: Mayo Clinic College of Medicine; 2004.
34. Parsons LS: Reducing bias in a propensity score matched-pair sample
using greedy matching techniques. In Proceedings of the Twenty-Sixth
Annual SAS (Users Group International Conference). Cary, NC: SAS Institute
Inc; 2001.
Jacob et al. BMC Medical Research Methodology 2013, 13:59 Page 13 of 13
http://www.biomedcentral.com/1471-2288/13/5935. Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, Vermeulen MJ:
Analysis of observational studies in the presence of treatment selection bias:
effects of invasive cardiac management on AMI survival using propensity
score and instrumental variable methods. JAMA 2007, 297:278–285.
36. Mamdani M, Sykora K, Li P, Normand SL, Streiner DL, Austin PC, et al:
Reader's guide to critical appraisal of cohort studies: Assessing potential
for confounding. BMJ 2005, 330:960–962.
37. Pisoni RL, Arrington CJ, Albert JM, Ethier J, Kimata N, Krishnan M, et al:
Facility hemodialysis vascular access use and mortality in countries
participating in DOPPS: an instrumental variable analysis. Am J Kidney Dis
2009, 53:475–491.
38. Kahn JM, Ten Have TR, Iwashyna TJ: The relationship between hospital
volume and mortality in mechanical ventilation: an instrumental variable
analysis. Health Serv Res 2009, 44:862–879.
39. Falcaro M, Povey AC, Fielder A, Nahit E, Pickles A: Estimating intervention
effects in a complex multi-level smoking prevention study. Int J Environ
Res Publ Health 2009, 6:463–477.
40. Greenland S: An introduction to instrumental variables for
epidemiologists. Int J Epidemiol 2000, 29:722–729.
41. Rhodes W, Pelissier B, Gaes G, Saylor W, Camp S, Wallace S: Alternative
solutions to the problem of selection bias in an analysis of federal
residential drug treatment programs. Eval Rev 2001, 25:331–369.
42. Brooks JM, McClellan M, Wong HS: The marginal benefits of invasive
treatments for acute myocardial infarction: does insurance coverage
matter? Inquiry 2000, 37:75–90.
43. Harris KM, Remler DK: Who is the marginal patient? Understanding
instrumental variables estimates of treatment effects. Health Serv Res
1998, 33:1337–1360.
44. Rassen JA, Brookhart MA, Glynn RJ, Mittleman MA, Schneeweiss S:
Instrumental variables I: instrumental variables exploit natural variation
in nonexperimental data to estimate causal relationships. J Clin Epidemiol
2009, 62(12):1226–1232.
45. Landrum MB, Ayanian JZ: Causal Effect of Ambulatory Specialiy Care on
Mortality Following Myocardial Infarction: A comparison of Propensity
Score and Instrumental Variable Analyses. Health Serv Outcome Res Meth
2001, 2:221–245.
46. Klabunde CN, Vernon SW, Nadel MR, Breen N, Seeff LC, Brown ML: Barriers
to colorectal cancer screening: a comparison of reports from primary
care physicians and average-risk adults. Med Care 2005, 43:939–944.
doi:10.1186/1471-2288-13-59
Cite this article as: Jacob et al.: Methodological approaches to
population based research of screening procedures in the presence of
selection bias and exposure measurement error: colonoscopy and
colorectal cancer outcomes in Ontario. BMC Medical Research
Methodology 2013 13:59.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
